Abstract Number: PB0922
Meeting: ISTH 2022 Congress
Theme: Venous Thromboembolism » Cancer Associated Thrombosis
Background: Cancer is a significant risk factor for venous thromboembolism (VTE) which applies not only to the risk of the first VTE event but also to the risk of VTE recurrence. The presence of thrombophilia may further increase the risks. However, thrombophilia testing is not usually performed in cancer patients.
Aims: The aim of our study was to assess the prevalence of thrombophilia in patients with cancer associated thromboembolism (CAT).
Methods: We retrospectively evaluated prospectively collected data of patients with active cancer and objectively confirmed VTE. The study was performed in a tertiary care hospital. We included the patients who had visited thrombosis clinic since 2006 to 2020. We obtained complete history of the patients and performed thrombophilia testing. All patients provided a written informed consent. For statistical evaluation, Student´s T-test and chi-square test were used.
Results: Of 87 patients with CAT (mean age 68.5±9.4; 36.8% females), 24.1% had a positive family history and 29.9% had a positive personal history of VTE. The prevalence of thrombophilia was 28.7% (FVL 17.2%, prothrombin gene mutation G20210A 2.3%, antithrombin deficiency 6.9% and antiphospholipid syndrome 3.4%). Comparing the CAT groups with and without thrombophilia, the age and gender distribution was similar (mean age 68.6 vs 68.5, P=0.939; females 44.0% vs 33.9%, P=0.375). In the group with CAT and thrombophilia, more patients had a positive family history of VTE (36.0% vs 19.4%, P=0.101) and a positive personal history of VTE (44.0% vs 24.2%, P=0.068) but the differences did not reach statistical significance.
Conclusion(s): The prevalence of thrombophilia in the patients with CAT is quite high, especially in those who already have a positive history of VTE. Larger and prospective studies should address the question whether selected patients with CAT might benefit from thrombophilia testing in assessing their risk of recurrence and tailoring secondary thromboprophylaxis.
To cite this abstract in AMA style:
Hirmerová J, Šubrt I, Hajšmanová Z. The Prevalence of Thrombophilia in Patients with Cancer Associated Thromboembolism [abstract]. https://abstracts.isth.org/abstract/the-prevalence-of-thrombophilia-in-patients-with-cancer-associated-thromboembolism/. Accessed April 19, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-prevalence-of-thrombophilia-in-patients-with-cancer-associated-thromboembolism/